ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2023
Clinical standards for the management of adverse effects during treatment for TB.
Open access · hybridAbstract read
In one paragraph
Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
9.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Adverse events in bedaquiline- and pretomanid-based regimens for drug-resistant tuberculosis from trial, implementation and pharmacovigilance studies.British journal of clinical pharmacology · 2026Pooled it
- Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists After Bowel Obstruction or Ileus: A Nationwide, Real-World, Database Study.Journal of evidence-based medicine · 2026Article
- Pharmacogenomics of antibacterial and antiviral therapies: Clinical actionability, evidence gaps, and future directions.Pharmacological reviews · 2026Review
- CYP2E1 and CYP2D6 in Anti-Tuberculosis Drug-Induced Liver Injury: Mechanisms, Epigenetic Regulation, and Translational Implications.Clinical and translational science · 2026Review
- Article
- Demographic and clinical correlates of discordant QuantiFERON TB Gold tuberculosis screening results in a low-incidence setting.Microbiology spectrum · 2026Article
- A systematic review of the outcomes of desensitization for delayed-type cutaneous adverse reactions induced by antituberculosis drugs.Asia Pacific allergy · 2026Review
- A rare case of unusual anti-tuberculosis drug reaction in disseminated tuberculosis with pre-existing Multisystem Inflammatory Syndrome in Children (MIS-C).BMC infectious diseases · 2026Article
- Cutaneous Tuberculosis Presenting as a Chronic Dermatologic Disorder.Case reports in dermatological medicine · 2026Article
- Rifampin: The Cause of Acute Tubular Injury-A Case Report.Case reports in nephrology · 2026Article
- Rifampin-induced Acute Kidney Injury Is Associated With Hemolysis and Drug Re-exposure.Kidney medicine · 2026Article
- Management of adverse events in TB care and active TB drug safety monitoring.Breathe (Sheffield, England) · 2026Article
- Clinical standards for antimicrobial stewardship in TB care.IJTLD open · 2025Article
- Incidence and predictors of mortality among persons with rifampicin-resistant tuberculosis and HIV in Mozambique.Scientific reports · 2025Article
- Evaluation of Social and Clinical Factors Associated with Adverse Drug Reactions Among Children with Drug-Resistant Tuberculosis in Pakistan.Tropical medicine and infectious disease · 2025Article
- An Update on the Clinical Management of HIV and Tuberculosis Co-Infection in Pregnancy: TB Preventative Therapy, Long-Acting ARVs, and Bedaquiline-Based Regimens.Current HIV/AIDS reports · 2025Review
- The Adverse Effects of Tuberculosis Treatment: A Comprehensive Literature Review.Medicina (Kaunas, Lithuania) · 2025Review
- Adequacy of recommendations for adverse event management in national and international treatment guidelines for rifampicin-susceptible tuberculosis: a systematic review.EClinicalMedicine · 2025Review
- A year in review - evaluating the launch of IJTLD OPEN.IJTLD open · 2025Article
- Managing Pulmonary Injury in Older Adults with Tuberculosis: The Role of Nursing Interventions.Journal of multidisciplinary healthcare · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
65 authors at 20 institutions in 23 countries.
K P SinghDepartment of Infectious diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia, Victorian Infectious Disease Unit, Royal Melbourne Hospital, VIC, Australia.
A C C CarvalhoLaboratório de Inovações em Terapias, Ensino e Bioprodutos (LITEB), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil.
R CentisServizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy.
L D AmbrosioPublic Health Consulting Group, Lugano, Switzerland.
G B MiglioriServizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy.
S G MpagamaKilimanjaro Christian Medical University College, Moshi, United Republic of Tanzania, Kibong´oto Infectious Diseases Hospital, Sanya Juu, Siha, Kilimanjaro, United Republic of Tanzania.
B C NguyenWoolcock Institute of Medical Research, Viet Nam and University of Sydney, NSW, Australia.
R E AarnoutseDepartment of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands.
A AleksaGrodno State Medical University, Grodno, Belarus.
R van AltenaAsian Harm Reduction Network (AHRN) and Medical Action Myanmar (MAM), Yangon, Myanmar.
P K BhavaniIndian Council of Medical Research-National Institute for Research in Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
M S BolhuisDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
S BorisovMoscow Research and Clinical Center for Tuberculosis Control, Moscow, Russia.
N van T Boveneind-VrubleuskayaDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, Department of Public Health TB Control, Metropolitan Public Health Services, The Hague, The Netherlands.
J BruchfeldDepartement of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Stokholm, Sweden, Departement of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
J A CamineroDepartment of Pneumology. University General Hospital of Gran Canaria "Dr Negrin", Las Palmas, Spain, ALOSA (Active Learning over Sanitary Aspects) TB Academy, Spain.
I CarvalhoPaediatric Department, Vila Nova de Gaia Hospital Centre, Vila Nova de Gaia Outpatient Tuberculosis Centre, Vila Nova de Gaia, Portugal.
J G ChoSydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia, Parramatta Chest Clinic, Parramatta, NSW, Australia.
L Davies ForsmanDepartement of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Stokholm, Sweden, Departement of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
M DedicoatDepartment of Infectious Diseases, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
K DhedaCentre for Lung Infection and Immunity Unit, Department of Medicine, Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, South Africa, South African Medical Research Council Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
K DooleyDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
J FurinDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
J M García-GarcíaTuberculosis Research Programme, SEPAR (Sociedad Española de Neumología y Cirugía Torácica), Barcelona, Spain.
A Garcia-PratsDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa, Department of Pediatrics, University of Wisconsin, Madison, WI, USA.
A C HesselingDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa.
S K HeysellDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
Y HuDepartment of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China.
H Y KimSydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
S MangaTuberculosis Department Latin American Society of Thoracic Diseases, Lima, Peru.
B J MaraisSydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Department of Infectious Diseases and Microbiology, The Children´s Hospital at Westmead, Westmead, NSW, Australia.
I MargineanuDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
A-G MärtsonCentre of Excellence in Infectious Diseases Research, Antimicrobial Pharmacodynamics and Therapeutics Group, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
M Munoz TorricoClínica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias, México City, Mexico.
H M NataprawiraDivision of Paediatric Respirology, Department of Child Health, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia.
E NunesDepartment of Pulmonology of Central Hospital of Maputo, Maputo, Mozambique, Faculty of Medicine of Eduardo Mondlane University, Maputo, Mozambique.
C W M OngInfectious Disease Translational Research Programme, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy, Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore.
R Otto-KnappGerman Central Committee Against Tuberculosis (DZK), Berlin, Germany.
D J PalmeroHospital Muniz and Instituto Vaccarezza, Buenos Aires, Argentina.
C A PeloquinInfectious Disease Pharmacokinetics Laboratory, College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA.
A RendonUniversidad Autonoma de Nuevo Leon, Facultad de Medicina, Neumología, CIPTIR, Monterrey, Mexico.
D Rossato SilvaFaculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
R RuslamiTB/HIV Research Centre, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia, Department of Biomedical Sciences, Division of Pharmacology and Therapy, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
A M I SaktiawatiDepartment of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia, Centre for Tropical Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia.
P SantosoDivision of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia.
H S SchaafDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa.
B SeaworthUniversity of Texas Health Science Center at Tyler, Tyler, TX, USA.
U S H SimonssonDepartment of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
R SinglaDepartment of TB & Respiratory Diseases, National Institute of TB & Respiratory Diseases, New Delhi, India.
A SkrahinaRepublican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus.
I SolovicNational Institute of Tuberculosis, Lung Diseases and Thoracic Surgery, Faculty of Health, Catholic University, Ružomberok, Vyšné Hágy, Slovakia.
S SrivastavaUniversity of Texas Health Science Center at Tyler, Tyler, TX, USA, Department of Medicine, The University of Texas at Tyler School of Medicine, TX, USA, Department of Pharmacy Practice, Texas Tech University Health Science Center, Dallas, TX, USA.
S L StockerSchool of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia, Department of Clinical Pharmacology and Toxicology, St Vincent´s Hospital, Sydney, NSW, Australia.
M G G SturkenboomDepartment of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
E M SvenssonDepartment of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands, Department of Pharmacy, Uppsala University, Uppsala, Sweden.
M TadoliniInfectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant´Orsola, Bologna, Italy, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
T A ThomasDivision of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA.
S TiberiBlizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
J TrubianoDepartment of Infectious diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia, Department of Infectious Diseases, Austin Hospital, Melbourne, VIC, Australia.
Z F UdwadiaP. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India.
A R VerhageDepartment of Paediatrics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
D H VuNational Drug Information and Adverse Drug Reaction Monitoring Centre, Hanoi University of Pharmacy, Hanoi, Vietnam.
O W AkkermanDepartment of Pulmonary Diseases and Tuberculosis, Groningen, Haren, the Netherlands, Tuberculosis Center Beatrixoord, University Medical Center Groningen, University of Groningen, Haren, the Netherlands.
J W C AlffenaarSydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.
J T Denholm
University Medical Center Groningen · NLUniversity of Groningen · NLIstituti Clinici Scientifici Maugeri · ITKarolinska Institutet · SEPadjadjaran University · IDStellenbosch University · ZAThe University of Melbourne · AUThe University of Sydney · AUUniversity of Virginia · USUppsala University · SEWestmead Hospital · AUCatholic University in Ruzomberok · SKCentral Scientific Research Institute of Tuberculosis Russian Academy of Medical Sciences · RUCentro Hospitalar de Vila Nova de Gaia · PTChildren's Hospital at Westmead · AUDr. Hasan Sadikin General Hospital · IDEduardo Mondlane University · MZFudan University · CNFundação Oswaldo Cruz · BRGrodno State Medical University · BY
Funding
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4MUrine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and AdultsR01AI137080 · NIAID · UNIVERSITY OF VIRGINIA · PI Scott K Heysell, Leonid Kagan · 2018 to 2026
$6.3MA randomized clinical trial of early empiric anti-Mycobacterium tuberculosis therapy for sepsis in sub-Saharan AfricaU01AI150508 · NIAID · UNIVERSITY OF VIRGINIA · PI HEYSELL, SCOTT K, MOORE, CHRISTOPHER CHARLES · 2020 to 2024
$3.3MMentoring Investigators in HIV and Tuberculosis Therapeutics ResearchK24AI150349 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DOOLEY, KELLY E. · 2020 to 2025
$789kNIAID NIH HHS K24 AI150349NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI137080NIAID NIH HHS U01 AI150508
Abstract
PubMed holds no abstract for this paper.
Indexed as
Drug-Related Side Effects and Adverse ReactionsHypersensitivityTuberculosisHealth PersonnelHumans
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.